Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Neoplasms 2Triple Negative Breast Neoplasms 1Skin Diseases 1Prostatic Neoplasms 1Neoplasms by Site 1Breast Diseases 1

Interventions

pembrolizumab 4Gemcitabine 4padeliporfin 3napabucasin 3Pemetrexed 3Paclitaxel 3Drug Therapy 3Cisplatin 3Carboplatin 3130-nm albumin-bound paclitaxel 3ribociclib 2palbociclib 2Mitomycin 2Gonadotropin-Releasing Hormone 2Fluorouracil 2Bevacizumab 2Anastrozole 2Albumin-Bound Paclitaxel 2AZD9833 2valrubicin 1selinexor 1pralsetinib 1patritumab 1palladium-bacteriopheophorbide 1linifanib 1ipatasertib 1enfortumab vedotin 1camrelizumab 1atezolizumab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Site × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡